Physician profile
Gary Cain
NPI 1336267392
$10,451.69
in general payments reported to CMS, 2019-2025
50 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,163 · 2022: $2,135 · 2023: $2,234 · 2024: $1,976 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,059 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,058.62 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,139.44 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,012.95 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $996.55 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $936.81 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $809.87 | 2021-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $482.43 | 2021-2025 | |
| Pfizer INC. | $459.56 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $348.72 | 2021-2025 | Belsomra, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $314.02 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $303.33 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.05 | 2021-2025 | Jardiance, Ofev |
| Lundbeck LLC | $285.40 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $282.09 | 2021-2025 | Rexulti |
| Abbott Laboratories | $252.22 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $212.66 | 2021-2024 | Veozah, Myrbetriq |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.